Tumor-specific
strategy
Comprehensive
service
Quality
assurance
Intellectual property:ACTL is a patented technology of Immuclin
Group of experts in oncology, immunology and virology ensures constant development of ACTL technology.
Tumor-targeted - High efficacy in recognizing and destroying cancer cells.
Toxicity free - pailess treatment with no side effects
Intergrative therapy - possible to work together with other treatments
Shortened duration for cell processing
Service networks across China, Asia and USA.
Exclusive partnership in appointed region with full support.
ACTL技术的生产不仅操作简便,而且符合标准化、产业化、大规模生产的条件。